Advertisement

Inflammation Research

, Volume 61, Issue 6, pp 535–539 | Cite as

Green tea consumption: an alternative approach to managing oral lichen planus

  • Jing Zhang
  • Gang ZhouEmail author
Review

Abstract

Oral lichen planus (OLP) is a T-cell-mediated inflammatory autoimmune disease, whose pathogenesis includes both antigen-specific and non-specific mechanisms. Antigen-specific mechanisms in OLP consist of antigen presentation, lymphocyte activation, proliferation and migration as well as keratinocyte apoptosis mediated by CD8+ cytotoxic T-cells, whereas non-specific mechanisms include mast cell degranulation and matrix metalloproteinase (MMP) activation in OLP lesions. Deficient antigen-specific transforming growth factor-β (TGF-β)-mediated immunosuppression may also contribute to the pathogenesis of OLP. In addition, OLP is considered to be a potentially malignant disorder with a malignant transformation rate of 0–5.3%. Green tea, especially epigallocatechin-3-gallate, possesses anti-inflammatory and chemopreventive properties. It can inhibit antigen presentation, T-cell activation, proliferation and migration, keratinocyte apoptosis, nuclear factor-kappaB (NF-кB) activation and MMP-9 activity, as well as regulated on activation, normal T-cell expressed and secreted (RANTES) expression, and can modulate the imbalance between TGF-β and interferon-γ signaling, all of which are involved in the pathogenesis of OLP. Thus, our hypothesis is that green tea consumption may decrease OLP incidence and provide a neoteric, nontoxic and inexpensive therapeutic strategy for OLP. Furthermore, green tea might be a possible agent for preventing malignancies in OLP.

Keywords

Green tea Epigallocatechin-3-gallate (EGCG) Oral lichen planus Pathogenesis Treatment 

Notes

Acknowledgments

This work was supported by a Grant (No. 30973311, No. 81170972) from the National Natural Science Foundation of China.

References

  1. 1.
    Roopashree MR, Gondhalekar RV, Shashikanth MC, George J, Thippeswamy SH, Shukla A. Pathogenesis of oral lichen planus––a review. J Oral Pathol Med. 2010;39:729–34.PubMedCrossRefGoogle Scholar
  2. 2.
    Sugerman PB, Savage NW, Walsh LJ, Zhao ZZ, Zhou XJ, Khan A, et al. The pathogenesis of oral lichen planus. Crit Rev Oral Biol Med. 2002;13:350–65.PubMedCrossRefGoogle Scholar
  3. 3.
    Lodi G, Scully C, Carrozzo M, Griffiths M, Sugerman PB, Thongprasom K. Current controversies in oral lichen planus: report on an international consensus meeting. Part 1. Viral infections and etiopathogenesis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2005;100:40–51.PubMedCrossRefGoogle Scholar
  4. 4.
    Warnakulasuriya S, Johnson NW, van der Waal I. Nomenclature and classification of potentially malignant disorders of the oral mucosa. J Oral Pathol Med. 2007;36:575–80.PubMedCrossRefGoogle Scholar
  5. 5.
    Cabrera C, Artacho R, Gimenez R. Beneficial effects of green tea––a review. J Am Coll Nutr. 2006;25:79–99.PubMedGoogle Scholar
  6. 6.
    Yang CS, Maliakal P, Meng X. Inhibition of carcinogenesis by tea. Annu Rev Pharmacol Toxicol. 2002;42:25–54.PubMedCrossRefGoogle Scholar
  7. 7.
    Yoneyama S, Kawai K, Tsuno NH, Okaji Y, Asakage M, Tsuchiya T, et al. Epigallocatechin gallate affects human dendritic cell differentiation and maturation. J Allergy Clin Immunol. 2008;121:209–14.PubMedCrossRefGoogle Scholar
  8. 8.
    Kawai K, Tsuno NH, Kitayama J, Okaji Y, Yazawa K, Asakage M, et al. Epigallocatechin gallate induces apoptosis of monocytes. J Allergy Clin Immunol. 2005;115:186–91.PubMedCrossRefGoogle Scholar
  9. 9.
    Wu D, Guo Z, Ren Z, Guo W, Meydani SN. Green tea EGCG suppresses T cell proliferation through impairment of IL-2/IL-2 receptor signaling. Free Radic Biol Med. 2009;47:636–43.PubMedCrossRefGoogle Scholar
  10. 10.
    Varilek GW, Yang F, Lee EY, deVilliers WJ, Zhong J, Oz HS, et al. Green tea polyphenol extract attenuates inflammation in interleukin-2-deficient mice, a model of autoimmunity. J Nutr. 2001;131:2034–9.PubMedGoogle Scholar
  11. 11.
    Ahmed S. Green tea polyphenol epigallocatechin 3-gallate in arthritis: progress and promise. Arthritis Res Ther. 2010;12:208.PubMedCrossRefGoogle Scholar
  12. 12.
    Fu Z, Zhen W, Yuskavage J, Liu D. Epigallocatechin gallate delays the onset of type 1 diabetes in spontaneous non-obese diabetic mice. Br J Nutr. 2011;105:1218–25.PubMedCrossRefGoogle Scholar
  13. 13.
    Hsu S, Dickinson D. A new approach to managing oral manifestations of Sjogren’s syndrome and skin manifestations of lupus. J Biochem Mol Biol. 2006;39:229–39.PubMedCrossRefGoogle Scholar
  14. 14.
    Carrozzo M, Thorpe R. Oral lichen planus: a review. Minerva Stomatol. 2009;58:519–37.PubMedGoogle Scholar
  15. 15.
    Sugerman PB, Savage NW, Zhou X, Walsh LJ, Bigby M. Oral lichen planus. Clin Dermatol. 2000;18:533–9.PubMedCrossRefGoogle Scholar
  16. 16.
    Ullmann U, Haller J, Decourt JP, Girault N, Girault J, Richard-Caudron AS, et al. A single ascending dose study of epigallocatechin gallate in healthy volunteers. J Int Med Res. 2003;31:88–101.PubMedGoogle Scholar
  17. 17.
    Farhi D, Dupin N. Pathophysiology, etiologic factors, and clinical management of oral lichen planus, part I: facts and controversies. Clin Dermatol. 2010;28:100–8.PubMedCrossRefGoogle Scholar
  18. 18.
    Sugerman PB, Satterwhite K, Bigby M. Auto-cytotoxic T cell clones in lichen planus. Br J Dermatol. 2000;142:449–56.PubMedCrossRefGoogle Scholar
  19. 19.
    Pae M, Ren Z, Meydani M, Shang F, Meydani SN, Wu D. Epigallocatechin-3-gallate directly suppresses T cell proliferation through impaired IL-2 utilization and cell cycle progression. J Nutr. 2010;140:1509–15.PubMedCrossRefGoogle Scholar
  20. 20.
    Nam S, Smith DM, Dou QP. Ester bond-containing tea polyphenols potently inhibit proteasome activity in vitro and in vivo. J Biol Chem. 2001;276:13322–30.PubMedCrossRefGoogle Scholar
  21. 21.
    Berges C, Haberstock H, Fuchs D, Miltz M, Sadeghi M, Opelz G, et al. Proteasome inhibition suppresses essential immune functions of human CD4+ T cells. Immunology. 2008;124:234–46.PubMedCrossRefGoogle Scholar
  22. 22.
    Kawai K, Tsuno NH, Kitayama J, Okaji Y, Yazawa K, Asakage M, et al. Epigallocatechin gallate attenuates adhesion and migration of CD8+ T cells by binding to CD11b. J Allergy Clin Immunol. 2004;113:1211–7.PubMedCrossRefGoogle Scholar
  23. 23.
    Yang F, Oz HS, Barve S, deVilliers WJ, McClain CJ, Varilek CW. The green tea polyphenol (−)-epigallocatechin-3-gallate blocks nuclear factor-kappa B activation by inhibiting I kappa B kinase activity in the intestinal epithelial cell line IEC-6. Mol Pharmacol. 2001;60:528–33.PubMedGoogle Scholar
  24. 24.
    Wheeler DS, Catravas JD, Odoms K, Denenberg A, Malhotra V, Wong HR. Epigallocatechin-3-gallate, a green tea-derived polyphenol, inhibits IL-1 beta-dependent proinflammatory signal transduction in cultured respiratory epithelial cells. J Nutr. 2004;134:1039–44.PubMedGoogle Scholar
  25. 25.
    Hong MH, Kim MH, Chang HJ, Kim NH, Shin BA, Ahn BW, et al. (−)-Epigallocatechin-3-gallate inhibits monocyte chemotactic protein-1 expression in endothelial cells via blocking NF-kappaB signaling. Life Sci. 2007;80:1957–65.PubMedCrossRefGoogle Scholar
  26. 26.
    Shin HY, Kim SH, Jeong HJ, Kim SY, Shin TY, Um JY, et al. Epigallocatechin-3-gallate inhibits secretion of TNF-alpha, IL-6 and IL-8 through the attenuation of ERK and NF-kappaB in HMC-1 cells. Int Arch Allergy Immunol. 2007;142:335–44.PubMedCrossRefGoogle Scholar
  27. 27.
    Zhou G, Xia K, Du GF, Chen XM, Xu XY, Lu R, et al. Activation of nuclear factor-kappa B correlates with tumor necrosis factor-alpha in oral lichen planus: a clinicopathologic study in atrophic-erosive and reticular form. J Oral Pathol Med. 2009;38:559–64.PubMedCrossRefGoogle Scholar
  28. 28.
    Santoro A, Majorana A, Bardellini E, Festa S, Sapelli P, Facchetti F. NF-kappaB expression in oral and cutaneous lichen planus. J Pathol. 2003;201:466–72.PubMedCrossRefGoogle Scholar
  29. 29.
    Barnes PJ, Karin M. Nuclear factor-κB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med. 1997;336:1066–71.PubMedCrossRefGoogle Scholar
  30. 30.
    Rhodus NL, Cheng B, Myers S, Bowles W, Ho V, Ondrey F. A comparison of the pro-inflammatory, NF-kappaB-dependent cytokines: TNF-alpha, IL-1-alpha, IL-6, and IL-8 in different oral fluids from oral lichen planus patients. Clin Immunol. 2005;114:278–83.PubMedCrossRefGoogle Scholar
  31. 31.
    Yang F, de Villiers WJ, McClain CJ, Varilek GW. Green tea polyphenols block endotoxin-induced tumor necrosis factor-production and lethality in a murine model. J Nutr. 1998;128:2334–40.PubMedGoogle Scholar
  32. 32.
    Zhou XJ, Sugerman PB, Savage NW, Walsh LJ. Matrix metalloproteinases and their inhibitors in oral lichen planus. J Cutan Pathol. 2001;28:72–82.PubMedCrossRefGoogle Scholar
  33. 33.
    Benesová Y, Vasku A, Novotná H, Litzman J, Stourac P, Beránek M, et al. Matrix metalloproteinase-9 and matrix metalloproteinase-2 as biomarkers of various courses in multiple sclerosis. Mult Scler. 2009;15:316–22.PubMedCrossRefGoogle Scholar
  34. 34.
    Ho YC, Yang SF, Peng CY, Chou MY, Chang YC. Epigallocatechin-3-gallate inhibits the invasion of human oral cancer cells and decreases the productions of matrix metalloproteinases and urokinase-plasminogen activator. J Oral Pathol Med. 2007;36:588–93.PubMedCrossRefGoogle Scholar
  35. 35.
    Demeule M, Brossard M, Pagé M, Gingras D, Béliveau R. Matrix metalloproteinase inhibition by green tea catechins. Biochim Biophys Acta. 2000;1478:51–60.PubMedCrossRefGoogle Scholar
  36. 36.
    Lee JH, Chung JH, Cho KH. The effects of epigallocatechin-3-gallate on extracellular matrix metabolism. J Dermatol Sci. 2005;40:195–204.PubMedCrossRefGoogle Scholar
  37. 37.
    Ahmed S, Pakozdi A, Koch AE. Regulation of interleukin-1beta-induced chemokine production and matrix metalloproteinase 2 activation by epigallocatechin-3-gallate in rheumatoid arthritis synovial fibroblasts. Arthritis Rheum. 2006;54:2393–401.PubMedCrossRefGoogle Scholar
  38. 38.
    Andriamanalijaona R, Kypriotou M, Baugé C, Renard E, Legendre F, Raoudi M, et al. Comparative effects of 2 antioxidants, selenomethionine and epigallocatechin-gallate, on catabolic and anabolic gene expression of articular chondrocytes. J Rheumatol. 2005;32:1958–67.PubMedGoogle Scholar
  39. 39.
    Yumei F, Zhou Y, Zheng S, Chen A. The antifibrogenic effect of (-)-epigallocatechin gallate results from the induction of de novo synthesis of glutathione in passaged rat hepatic stellate cells. Lab Invest. 2006;86:697–709.PubMedCrossRefGoogle Scholar
  40. 40.
    Lodi G, Scully C, Carrozzo M, Griffiths M, Sugerman PB, Thongprasom K. Current controversies in oral lichen planus; report of an international consensus meeting––Part 2. Management and malignant transformation. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2005;100:164–78.PubMedCrossRefGoogle Scholar
  41. 41.
    Li N, Sun Z, Han C, Chen J. The chemopreventive effects of tea on human oral precancerous mucosa lesions. Proc Soc Exp Biol Med. 1999;220:218–24.PubMedCrossRefGoogle Scholar
  42. 42.
    Fujiki H, Suganuma M, Imai K, Nakachi K. Green tea: cancer preventive beverage and/or drug. Cancer Lett. 2002;188:9–13.PubMedCrossRefGoogle Scholar
  43. 43.
    Schwarz B, Bischof HP, Kunze M. Coffee, tea, and lifestyle. Prev Med. 1994;23:377–84.PubMedCrossRefGoogle Scholar
  44. 44.
    Maeda-Yamamoto M, Ema K, Shibuichi I. In vitro and in vivo anti-allergic effects of ‘benifuuki’ green tea containing O-methylated catechin and ginger extract enhancement. Cytotechnology. 2007;55:135–42.PubMedCrossRefGoogle Scholar
  45. 45.
    Basu A, Sanchez K, Leyva MJ, Wu M, Betts NM, Aston CE, et al. Green tea supplementation affects body weight, lipids, and lipid peroxidation in obese subjects with metabolic syndrome. J Am Coll Nutr. 2010;29:31–40.PubMedGoogle Scholar
  46. 46.
    Hernández Figueroa TT, Rodríguez-Rodríguez E, Sánchez-Muniz FJ. The green tea, a good choice for cardiovascular disease prevention? Arch Latinoam Nutr. 2004;54:380–94Google Scholar
  47. 47.
    Friedman M. Overview of antibacterial, antitoxin, antiviral, and antifungal activities of tea flavonoids and teas. Mol Nutr Food Res. 2007;51:116–34.PubMedCrossRefGoogle Scholar
  48. 48.
    Yu H, Oho T, Tagomori S, Morioka T. Anticariogenic effects of green tea. Fukuoka Igaku Zasshi. 1992;83:174–80.PubMedGoogle Scholar
  49. 49.
    Yun JH, Pang EK, Kim CS, Yoo YJ, Cho KS, Chai JK, et al. Inhibitory effects of green tea polyphenol (–)-epigallocatechin gallate on the expression of matrix metalloproteinase-9 and on the formation of osteoclasts. J Periodontal Res. 2004;39:300–7.PubMedCrossRefGoogle Scholar
  50. 50.
    Singh R, Akhtar N, Haqqi TM. Green tea polyphenol epigallocatechin-3-gallate: inflammation and arthritis. Life Sci. 2010;86:907–18.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Basel AG 2012

Authors and Affiliations

  1. 1.The State Key Laboratory Breeding Base of Basic Science of Stomatology (Hubei-MOST) and Key Laboratory of Oral Biomedicine Ministry of Education, School and Hospital of StomatologyWuhan UniversityWuhanPeople’s Republic of China
  2. 2.Department of Oral Medicine, School and Hospital of StomatologyWuhan UniversityWuhanPeople’s Republic of China

Personalised recommendations